AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Quanterix Corporation to Present at 38th Annual J.P. Morgan Healthcare Conference

January 10, 2020 GMT

BILLERICA, Mass.--(BUSINESS WIRE)--Jan 10, 2020--

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that its President, Chairman and Chief Executive Officer, Kevin Hrusovsky, will be presenting on the company’s growth and vision for the fourth consecutive year at the 38 th Annual J.P. Morgan Healthcare Conference in San Francisco. Hrusovsky’s session will take place on Wednesday, Jan. 15, 2020 at 4 p.m., PST (7 p.m., EST) in California East, Westin St. Francis, with a Q&A session directly following at 4:30 p.m., PST (7:30 p.m., EST) in the Yorkshire Room, Westin St. Francis.

In the two years since the Company’s very successful initial public offering, Quanterix has continued to achieve accelerated double-digit, year-over-year growth in each full quarter. The Company has had several critical milestones and achievements, including strategic acquisitions and agreements, multiple product launches that build on the renowned Simoa technology platform, new additions to its leadership team, raised nearly $120 million in 2019, continued growing in scientific publications and expanded the biomarker menu.

“Our team is relentless in its drive to change how researchers and pharmaceutical companies approach drug development and early disease detection using biomarkers,” said Hrusovsky. “Our customers and collaborators have made strong strides across neurology, with a groundswell of groundbreaking research validating neurofilament light (Nf-L) as a blood-based biomarker for measuring neurodegeneration. Oncology is witnessing a similar opportunity with Simoa. We are excited to discuss the unprecedented opportunity we have before us in the research markets and ultimately clinical diagnostic markets.”

Significant 2019 Achievements:

“This past year was a testament to what can be accomplished when you bring the right people, determination and technology together,” continued Hrusovsky. “We are encouraged by how our growth catalysts have all lined up for 2020 and feel our market opportunity is compelling.”

Webcast Information

To access the live webcast of Quanterix’ presentation at the 38 th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 15, 2020 at 4 p.m., PST, please visit https://jpmorgan.metameetings.net/events/hc20/sessions/29706-quanterix-corporation/webcast. To access the subsequent Q&A session with Hrusovsky on Wednesday, Jan. 15, 2020 at 4:30 p.m., PST, please visit https://jpmorgan.metameetings.net/events/hc20/sessions/30008-quanterix-corporation-q-a/webcast. Replays of the webcasts will be available for a limited period following the conference.

About Quanterix

Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts. For additional information, please visit https://www.quanterix.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200110005506/en/

CONTACT: Media Contacts:

PAN Communications

Staci Didner, (407) 734-7325

quanterix@pancomm.com

Investor Relations Contact:

Stephen Hrusovsky

(774) 278-0496

shrusovsky@quanterix.com

KEYWORD: CALIFORNIA MASSACHUSETTS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: RESEARCH CLINICAL TRIALS BIOTECHNOLOGY OTHER HEALTH HEALTH PHARMACEUTICAL GENERAL HEALTH OTHER SCIENCE SCIENCE

SOURCE: Quanterix

Copyright Business Wire 2020.

PUB: 01/10/2020 02:03 PM/DISC: 01/10/2020 02:03 PM

http://www.businesswire.com/news/home/20200110005506/en